CompletedNCT00663442
Methylphenidate or placebo for ADHD in children and teens
About this title
Read the official source — NCT00663442Researchers studied OROS methylphenidate to find out how it affected ADHD symptoms in people with ADHD.
Medication studyAges 6–17United States
Understand this study
What did researchers investigate?
Researchers studied OROS methylphenidate to find out how it affected ADHD symptoms in people with ADHD.
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- ChicagoSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 1999
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- University of Illinois Chicago
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00663442
- Official title
Show the full official title
Dose Response Pharmacogenetic Study of ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chicago
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied OROS methylphenidate to find out how it affected ADHD symptoms in people with ADHD.
Who is behind this study?
The study sponsor is University of Illinois Chicago, a university.
Did this study involve medication?
Yes. The study involved medication, including OROS methylphenidate.
Who was this study for?
Listed age limits: 6 years to 17 years.
